The Japanese pharmaceutical industry, a vital component of global innovation, faces a talent gap that resonates across multinational corporations. While Japan possesses a wealth of highly skilled professionals, a notable communication disparity impedes recruitment and career advancement, particularly in global…
REGULATORY
SanBio’s Lead Cell Therapy Up for Review Again on June 19
SanBio’s lead cell therapy candidate SB623 will come up for renewed discussion regarding its regulatory approval at a health ministry advisory meeting on June 19 after additional quality data were submitted by the company. The renewed review will be held…
To read the full story
Related Article
- SanBio, Minaris Aim to Expand Global Reach of Akuugo
June 20, 2025
- SanBio Inches Closer to Cell Therapy Shipment with Partial Change Filing
June 13, 2025
- SanBio’s Cell Therapy Akuugo Scores Conditional Approval
August 1, 2024
- SanBio Says Its Lead Cell Therapy Could Be Shipped from 2025 If All Goes Well
June 21, 2024
- SanBio’s Lead Cell Therapy in Line for Conditional Nod but Can’t Be Shipped Until Comparability Is Confirmed
June 20, 2024
- SanBio to Submit Additional Data to Obtain Approval for Lead Cell Therapy
March 27, 2024
- Japan Shelves Decision on SanBio’s Lead Cell Therapy on Quality Concerns
March 26, 2024
REGULATORY
- LDP Official: Higher Tax Revenue Could Fund Expansion of Minimum NHI Prices, Re-Pricing for Unprofitable Products
June 20, 2025
- Japan Puts a Hold on Coverage Discussions for Elevidys over Safety Concerns
June 19, 2025
- Japan to Delete 16 Drugs from NHI Price List under New Streamlined Process
June 19, 2025
- LDP Lawmakers Seek Early Male NIP Coverage for HPV Jabs
June 18, 2025
- Generic Fund Is to Support Costs Tied to Product Consolidation: Official
June 18, 2025
Following the launch of two new therapies since last year, Japan has seen fresh moves in drug development for amyotrophic…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…